Clinical trials: Psoriasis
Pharmacokinetics, Safety Issues
A Clinical Study With Adalimumab Biosimilar
The study aims to evaluate the pharmacokinetic profile, safety profile, and immunogenic potential of adalimumab of a new citrate-free formulation of adalimumab (Adalimumab Richmond) [Test Product] vs.
- Trial name
- NCT06291948
- Testing
- Humira® (adalimumab) AC Pen [Reference Product], Adalimumab Richmond [Test Product]
- Where
- Argentina
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Plaque Psoriasis.
ASIS for Enbrel in Plaque Psoriasis
AUTOMATIC SUBDERMAL INJECTOR SYSTEM (ASIS) Corporation has developed and patented the only automatic injection system for delivery of injectable products to the optimum spot, just outside of the fascia, which exists subdermally…
- Trial name
- ASISinPP (NCT02112097)
- Testing
- Gadolinium, Efficacy of Enbrel subcutaneously at Week 12, Efficacy of Enbrel subcutaneously at Week 24
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- ASIS Corporation
Psoriasis
Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis
Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis
- Trial name
- NCT02785159
- Testing
- IDP-118 Lotion, Tazorac Cream, IDP-118 Vehicle Lotion
- Where
- 14 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Dermatitis, Atopic
A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream
This will be an open-label, non-randomized, single-center study to assess the residency of GSK2894512 in the skin of healthy adult male volunteers with normal barrier function.
- Trial name
- NCT02411162
- Testing
- Combination therapy GSK2894512 Cream A + GSK2894512 Cream B, Combination therapy Vehicle Cream A + Vehicle Cream B
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Stiefel, a GSK Company
Psoriasis
A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis
The purpose of this study is to evaluate how well LY3316531 is tolerated and what side effects may occur in healthy participants and participants with psoriasis.
- Trial name
- NCT03418493
- Testing
- LY3316531 - IV, LY3316531 - SC
- Where
- 2 sites in United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Psoriasis
Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy Subjects
It is a randomized, double-blinded, single-dose, 3-arm parallel, comparative study to evaluate the pharmacokinetics, safety and immunogenicity of BAT2206 Injection vs Stelara® (EU-licensed and US-licensed) in healthy Chinese male…
- Trial name
- NCT04371185
- Testing
- BAT2206, Stelara(US-licensed), Stelara(EU-licensed)
- Where
- China
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Bio-Thera Solutions
Bioavailability of ASP015K, Pharmacokinetics of ASP015K
A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015K
The purpose of this study is to determine the relative bioavailability and pharmacokinetic profiles from three strengths of a new tablet formulation of ASP015K and to evaluate the safety and tolerability after a single dose of…
- Conditions
- Bioavailability of ASP015K, Pharmacokinetics of ASP015K, Healthy Subjects
- Trial name
- NCT01486017
- Testing
- ASP015K
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Psoriasis Vulgaris
Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects
This trial is looking at whether the LEO 90100 foam causes irritation of the skin in healthy Japanese male adults without psoriasis.
- Trial name
- NCT03442244
- Testing
- LEO 90100 foam, Vehicle of LEO 90100 foam
- Where
- Japan
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Psoriatic Arthritis
A Study on Pharmacokinetics and Safety of BAT2506 Injection Versus Simponi®
This is a randomized, double-blind, parallel three-arm, and single-dose Phase I clinical study, designed to compare the similarity of pharmacokinetics, safety and immunogenicity between BAT2506 Injection and Simponi® (EU-licensed…
- Trial name
- NCT05332730
- Testing
- BAT2506 injection, Simponi® (EU commercially available product), Simponi® (US commercially available product)
- Where
- China
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Bio-Thera Solutions
Psoriasis Vulgaris
Vasoconstriction Trial With LEO 90100 Aerosol Foam
Vasoconstriction study with LEO 90100
- Trial name
- NCT02973776
- Testing
- LEO 90100 aerosol foam, Dermoval®/Dermovate®, Diprosone
- Where
- France
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Plaque Psoriasis
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Plaque Psoriasis
- Trial name
- NCT02932878
- Testing
- DSXS topical
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Healthy, Psoriasis
A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970
The main purpose of this study is to evaluate the safety and tolerability of GLPG3970 in healthy volunteers after single oral administrations of GLPG3970 (SAD), compared to placebo (part 1 and 1bis) and after multiple (for 14…
- Trial name
- NCT04106297
- Testing
- GLPG3970 oral solution, GLPG3970 capsule
- Where
- 3 sites in Belgium, Moldova and 1 more
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Psoriasis Vulgaris
Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100
The purpose of this study is to determine the skin irritation potential and sensitisation potential of LEO 90100 and the vehicle after repeated applications on the skin of healthy subjects.
- Trial name
- NCT01935869
- Testing
- LEO 90100, Vehicle, Petrolatum ointment
- Where
- France
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with…
- Trial name
- BE UNIQUE (NCT06506916)
- Testing
- bimekizumab
- Where
- 14 sites in United States, Germany and 1 more
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Healthy Volunteers, Psoriasis
A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis
This is a phase 1, randomized, single-center, 3-part, study to assess the safety, tolerability, PK, and PD, of single and multiple doses of CC-92252 in healthy adult subjects and multiple doses of CC-92252 in adult subjects with…
- Trial name
- NCT03971825
- Testing
- CC-92252
- Where
- Germany
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Celgene
Psoriasis
HPP737 Substance Balance Study in Human
Main research purpose 1. Quantitative analysis of the total amount of radioactivity in excreta (urine and feces) of male healthy subjects after oral administration of [14C]HPP737, to obtain the cumulative excretion rate and main…
- Trial name
- NCT06584058
- Testing
- HPP737
- Where
- China
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Newsoara Biopharma Co., Ltd.
Psoriasis
Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants
This is a Phase 1, first-in-human (FIH), randomized, double-blind, single-dose, parallel-group, 3-arm study to compare PK, safety, tolerability, and immunogenicity profiles of CKD-704, EU-approved Skyrizi, and US-licensed Skyrizi…
- Trial name
- NCT07258745
- Testing
- SKYRIZI, CKD-704
- Where
- Poland
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Psoriasis (PsO)
A Study to Assess Deucravacitinib Safety in Pregnancy
The purpose of this study is to assess pregnancy and infant outcomes among pregnant participants enrolled in an established North American pregnancy registry (Organization of Teratology Information Specialists [OTIS]) who were…
- Trial name
- NCT07017699
- Testing
- Deucravacitinib, Other systemic treatments for PsO
- Where
- United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy, Atopic Dermatitis
A Study to Determine the Safety and Sensitizing Potential of HAT1 Topical Products Using Skin Sensitivity Patch Tests
The objective of this clinical study is to assess the irritation and sensitisation potential of HAT1 topical products after repeated patch applications to healthy human participants by following conventional Repeated Insult…
- Conditions
- Healthy, Atopic Dermatitis, Psoriasis
- Trial name
- NCT03406117
- Testing
- HAT1, Saline Solution
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Haus Bioceuticals
Psoriasis
Study to Assess the Safety and Tolerability of PBF-1650 in Healthy Volunteers.
Single center, randomized, double-blind, placebo-controlled clinical study to assess the safety and tolerability of PBF-1650 in order to obtain the Maximum Tolerated Dose (MTD).
- Trial name
- ADENOIMMUNE (NCT03798236)
- Testing
- PBF-1650 oral capsules
- Where
- Spain
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Palobiofarma SL